Drug Trial Radar · NCT02129751
Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
246
Planned (sponsor's estimate)
Start
Jul 1, 2027
Primary completion
Jul 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety
Conditions
- Major Depressive Disorder
Interventions
bupropion hydrobromideDrug
study drug
PlaceboDrug
placebo arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from Baseline to EOT in total CDRS-R (raw) scoreTime frame: Baseline and 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.